42115-48-0

Basic information

• Product Name: 2-BROMOBUTYRIC ACID N-BUTYL ESTER
• Synonyms: N-BUTYL-A-BROMOBUTYRATE;2-BROMOBUTYRIC ACID N-BUTYL ESTER;BUTYL A-BROMOBUTYRATE;butyl 2-bromobutyrate;N-BUTYL 2-BROMOBUTYRATE 99%;2-Bromobutyric acid butyl ester;2-Bromobutanoic acid butyl ester
• CAS NO: 42115-48-0
• Molecular Formula: C₈H₁₅BrO₂
• Molecular Weight: 223.11
• EINECS: 255-660-4
• Mol File: 42115-48-0.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 212°Cat760mmHg
• Flash Point: 91.4°C
• Appearance: /
• Density: 1.256g/cm³
• Vapor Pressure: 0.177mmHg at 25°C
• Refractive Index: 1.459
• CAS DataBase Reference: 2-BROMOBUTYRIC ACID N-BUTYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-BROMOBUTYRIC ACID N-BUTYL ESTER(42115-48-0)
• EPA Substance Registry System: 2-BROMOBUTYRIC ACID N-BUTYL ESTER(42115-48-0)

Safety Data

• Hazardous Substances Data: 42115-48-0(Hazardous Substances Data)

Usage

General Description

2-Bromobutyric acid n-butyl ester is a organic compound with the molecular formula C8H15BrO2. It is a colorless liquid with a slightly fruity odor and is commonly used as a chemical intermediate. 2-Bromobutyric acid n-butyl ester is primarily used in the production of pharmaceuticals and agrochemicals. It is also used in the synthesis of other organic compounds and as a solvent or reagent in chemical reactions. The compound is considered to be hazardous, with potential health effects including respiratory and skin irritation, and it should be handled and stored with proper safety precautions.

InChI:InChI=1/C8H15BrO2/c1-3-5-6-11-8(10)7(9)4-2/h7H,3-6H2,1-2H3

Upstream product

• 80-58-0 2-Bromobutyric acid 
• 71-36-3 butan-1-ol 

Relevant articles and documents

Novel ibuprofen prodrugs with improved pharmacokinetics and non-ulcerogenic potential

In the present study, we evaluated the anti-inflammatory activity with pharmacokinetic, ulcerogenic properties of various synthesized prodrugs of ibuprofen in experimental animals. Prodrugs 2, 6, 9, 10, 12, and 14 were found to possess significant anti-inflammatory activity with almost non-ulcerogenic potential than standard drug ibuprofen 1a in both normal and inflammation-induced rats. Metabolic stability of prodrugs 2, 6, 9, 10, 12, and 14 were also studied in rat liver microsomes and oral bioavailability was determined by estimating area under curve (AUC) and plasma concentration of these prodrugs at various time intervals. The experimental findings elicited higher AUC and plasma concentration at 1 and 2 h indicating improved oral bioavailability as compared to parent ibuprofen. These prodrugs are found to have least gastric ulceration with retain anti-inflammatory activity observed in experimental animals. Therefore, present experimental findings demonstrated significant improvement of various pharmacokinetic properties with least ulcerogenic potential of ester prodrugs of ibuprofen an anti-inflammatory agent